Modified · EXECUTIVE SUMMARY

During the first quarter of In 2026, we made meaningful progress advancing our pipeline, highlighted by: (i) positive interim Phase III results from the SUCCESSOR‐2 study of oral mezigdomide in RRMMFDA acceptance of our NDA for iberdomide in RRMM with a PDUFA date of August 17, 2026; (ii) positive Phase III results from the SCOUT-HCM trial of Camzyos in adolescents with symptomatic oHCMFDA acceptance of our NDA for mezigdomide in RRMM with a PDUFA date of May 13, 2027; (iii) positive top‐line interim Phase II results from a Phase II trial for Reblozylthe ROSETTA Lung-02 study of pumitamig in adultspatients with Alpha (α)-Thalassemia, previously untreated advanced NSCLC; (iv) positive interim top‐line results from atwo Phase III trialstudies conducted in China for iza-bren in previously treatedheavily pretreated, unresectable locally advanced or metastatic TNBC, and recurrent or metastatic ESCC; and (v) FDA acceptance of our NDAsNDA for iberdomideCamzyos in combinationadolescents with standard therapy for patients with RRMMsymptomatic oHCM with a PDUFA date of September 30, 2026. Additionally, Sotyktu was approved in the U.S. and EU for the treatment of adults with active PsA and Opdivo was approved in the U.S. and EU for cHL.